# Altimmune, Inc. (ALT) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Altimmune, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/ALT/mda/fy2025/): filed 2026-03-06; accession 0001326190-26-000018 (https://www.sec.gov/Archives/edgar/data/1326190/000132619026000018/alt-20251231x10k.htm); latest 10-K
- [FY 2024 MD&A](/company/ALT/mda/fy2024/): filed 2025-02-27; accession 0001326190-25-000015 (https://www.sec.gov/Archives/edgar/data/1326190/000132619025000015/alt-20241231x10k.htm)
- [FY 2023 MD&A](/company/ALT/mda/fy2023/): filed 2024-03-27; accession 0001326190-24-000010 (https://www.sec.gov/Archives/edgar/data/1326190/000132619024000010/alt-20231231x10k.htm)
- [FY 2022 MD&A](/company/ALT/mda/fy2022/): filed 2023-02-28; accession 0001326190-23-000008 (https://www.sec.gov/Archives/edgar/data/1326190/000132619023000008/alt-20221231x10k.htm)
- [FY 2021 MD&A](/company/ALT/mda/fy2021/): filed 2022-03-15; accession 0001558370-22-003659 (https://www.sec.gov/Archives/edgar/data/1326190/000155837022003659/alt-20211231x10k.htm)

Back to /company/ALT/